Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday - Robo.ai ( NASDAQ:AIIO ) , Aquestive Therapeutics ( NASDAQ:AQST )
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. ( NASDAQ: CRNX ) rose sharply during Friday's session after the FDA approved PALSONIFY. Also, Baird and JMP Securities raised their respective price targets on ...
FDA Should Delay Allergic Reaction Treatment: ARS Pharma - ARS Pharmaceuticals ( NASDAQ:SPRY ) , Aquestive Therapeutics ( NASDAQ:AQST )
ARS Pharmaceuticals Inc. SPRY filed a petition Monday urging the FDA to delay approval of Aquestive Therapeutics Inc.'s AQST experimental epinephrine treatment, citing safety, dosing, and real-world use concerns. The filing requests that the FDA withhold approval of AQST-109, a sublingual film ...
Aquestive Therapeutics ( AQST ) Soars 14.8%: Is Further Upside Left in the Stock?
Aquestive Therapeutics (AQST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
CoreWeave, Barrick Mining, FedEx And Other Big Stocks Moving Higher On Friday - Barrick Mining ( NYSE:B ) , Aquestive Therapeutics ( NASDAQ:AQST )
U.S. stocks were higher, with the Nasdaq Composite gaining more than 100 points on Friday. Shares of CoreWeave, Inc. CRWV rose sharply during Friday's session after Loop Capital initiated coverage with a Buy rating and announced a $165 price target. CoreWeave shares jumped 4.8% to $127.15 on ...
AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA
Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.
Shoe Carnival, American Eagle, Ciena, Victoria's Secret And Other Big Stocks Moving Higher On Thursday - AirNet Technology ( NASDAQ:ANTE ) , American Eagle Outfitters ( NYSE:AEO )
U.S. stocks were higher, with the Dow Jones index gaining over 200 points on Thursday. Shares of Shoe Carnival, Inc. SCVL rose sharply during Thursday's session after the company reported second-quarter EPS above estimates and raised its FY2025 EPS outlook, despite cutting its sales guidance.
Why Is Aquestive Therapeutics Stock Soaring Thursday? - Aquestive Therapeutics ( NASDAQ:AQST )
FDA skips advisory committee review for Aquestive's Anaphylm sublingual allergy film. The target action date for Anaphylm's approval is set for January 31, 2026. September's volatility catalysts are coming. Find out how to trade new inflation reports and fed signals here → The U.S.
Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™
WARREN, N.J., Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc. ( NASDAQ: AQST ) ( "Aquestive" or the "Company" ) , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today ...
Is Aquestive Therapeutics ( AQST ) Stock Outpacing Its Medical Peers This Year?
Here is how Aquestive Therapeutics (AQST) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock - Aquestive Therapeutics ( NASDAQ:AQST )
WARREN, N.J., Aug. 14, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc.
Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock
WARREN, N.J., Aug. 14, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc. ( NASDAQ: AQST ) ( "Aquestive" or the "Company" ) , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced ...
Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ ( epinephrine ) Sublingual Film - Aquestive Therapeutics ( NASDAQ:AQST )
Anaphylm launch funding of $75 million committed by RTW, subject to FDA approval of Anaphylm and other conditions Strategic financing will further strengthen the Company's balance sheet in advance of potential commercialization of Anaphylm for the emergency treatment of allergic reactions, ...
Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ ( epinephrine ) Sublingual Film
WARREN, N.J., Aug. 14, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc. ( NASDAQ: AQST ) ( "Aquestive" or the "Company" ) , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced ...
Aquestive Therapeutics ( AQST ) Reports Q2 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of +22.22% and -9.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET - Aquestive Therapeutics ( NASDAQ:AQST )
WARREN, N.J., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc.
USANA Health Sciences ( USNA ) Q2 Earnings and Revenues Top Estimates
USANA Health (USNA) delivered earnings and revenue surprises of +37.04% and +4.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer - Aquestive Therapeutics ( NASDAQ:AQST )
WARREN, N.J., July 22, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc.
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer
WARREN, N.J., July 22, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc. ( NASDAQ: AQST ) ( "Aquestive" or the "Company" ) , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced ...
Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ ( epinephrine ) Sublingual Film - Aquestive Therapeutics ( NASDAQ:AQST )
New Drug Submission meeting scheduled with Health Canada for the third quarter of 2025 Initial briefing book submitted for review to the European Medicines Agency WARREN, N.J., July 15, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc.
Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ ( epinephrine ) Sublingual Film
WARREN, N.J., July 15, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc. ( NASDAQ: AQST ) ( "Aquestive" or the "Company" ) , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today ...
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
WARREN, N.J., July 07, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) ( "Aquestive" or the "Company" ) , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today ...
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions - Aquestive Therapeutics ( NASDAQ:AQST )
FDA assigns PDUFA target action date of January 31, 2026 WARREN, N.J., June 16, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc. AQST ( "Aquestive" or the "Company" ) , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative ...
Aquestive Therapeutics ( AQST ) Reports Q1 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -41.18% and 28.14%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical ( COLL ) Q1 Earnings and Revenues Surpass Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 4.20% and 3.08%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference - Aquestive Therapeutics ( NASDAQ:AQST )
WARREN, N.J., May 05, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc.
Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET
WARREN, N.J., May 01, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc. ( NASDAQ: AQST ) ( "Aquestive" or the "Company" ) , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced ...
Strength Seen in Recursion Pharmaceuticals ( RXRX ) : Can Its 27.7% Jump Turn into More Strength?
Recursion Pharmaceuticals (RXRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium - Aquestive Therapeutics ( NASDAQ:AQST )
WARREN, N.J., April 09, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc.
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
WARREN, N.J., April 09, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) ( "Aquestive" or the "Company" ) , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today ...
Aquestive Therapeutics Concludes FDA Application For Allergy Drug With Encouraging Pediatric Trial Data - Aquestive Therapeutics ( NASDAQ:AQST )
Aquestive submitted Anaphylm's NDA to the FDA, expecting potential acceptance in Q2 2025, with a planned launch in Q1 2026 if approved. The pediatric study in 32 patients showed PK results consistent with adult data, with no serious adverse events reported.
Aquestive Therapeutics ( AQST ) Reports Q4 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -35.71% and 12.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Xencor ( XNCR ) Reports Q4 Loss, Tops Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of 25.30% and 293.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in United Therapeutics ( UTHR ) : Can Its 4.9% Jump Turn into More Strength?
United Therapeutics (UTHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Aquestive Therapeutics to Present New Findings on Anaphylm™ ( Epinephrine Sublingual Film ) at the 2025 AAAAI Annual Meeting - Aquestive Therapeutics ( NASDAQ:AQST )
Data show Anaphylm maintains consistent stability and potency under extreme temperature and real-world conditions, including heat, freezing, and water submersion New findings demonstrate dosing of Anaphylm results in consistent epinephrine absorption without impacting safety or pharmacodynamic ( ...
Aquestive Therapeutics to Present New Findings on Anaphylm™ ( Epinephrine Sublingual Film ) at the 2025 AAAAI Annual Meeting
WARREN, N.J., Feb. 12, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc. ( NASDAQ: AQST ) ( "Aquestive" or the "Company" ) , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced ...
Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference - Aquestive Therapeutics ( NASDAQ:AQST )
WARREN, N.J., Feb. 04, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc.
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® ( diazepam ) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five - Aquestive Therapeutics ( NASDAQ:AQST )
WARREN, N.J., Dec. 19, 2024 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc. AQST ( "Aquestive" or the "Company" ) , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the U.S.
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside - Aquestive Therapeutics ( NASDAQ:AQST )
Cantor initiated coverage on Aquestive Therapeutics, Inc. AQST, a pharmaceutical company with five commercialized products. The company also collaborates with pharmaceutical companies to bring new molecules to market using its technologies, like PharmFilm.
Aquestive Therapeutics ( AQST ) Reports Q3 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -8.33% and 6.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
WARREN, N.J., Nov. 04, 2024 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) ( "Aquestive" or the "Company" ) , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, reported ...
Corcept Therapeutics ( CORT ) Tops Q3 Earnings and Revenue Estimates
Corcept (CORT) delivered earnings and revenue surprises of 51.85% and 6.07%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome ( OAS ) Challenge Study for Anaphylm™ ( epinephrine ) Sublingual Film - Aquestive Therapeutics ( NASDAQ:AQST )
Completed OAS challenge study meets both primary and secondary endpoints Demonstrates rapid resolution of allergen-related symptoms beginning two minutes after administration Pharmacokinetic ( PK ) profile after allergen exposure comparable to non-allergen PK profile
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate - Aquestive Therapeutics ( NASDAQ:AQST )
On Friday, Aquestive Therapeutics, Inc. AQST hosted a virtual investor day highlighting the company's Anaphylm ( epinephrine ) Sublingual Film and AQST-108 ( epinephrine ) Topical Gel. Aquestive said it completed enrollment in its remaining supportive study for Anaphylm, the oral allergy ...
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day - Aquestive Therapeutics ( NASDAQ:AQST )
Announces completion of enrollment in its oral allergen challenge study for the development of its late-stage pipeline program, Anaphylm™ ( epinephrine ) Sublingual Film Outlines the development strategy for the Company's next pipeline product candidate, AQST-108 ( epinephrine ) Topical Gel ...
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
WARREN, N.J., Sept. 27, 2024 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc. ( NASDAQ: AQST ) ( "Aquestive" or the "Company" ) , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today hosted a ...
Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th - Aquestive Therapeutics ( NASDAQ:AQST )
WARREN, N.J., Sept. 09, 2024 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc.
Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
WARREN, N.J., Sept. 09, 2024 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc. ( NASDAQ: AQST ) ( "Aquestive" or the "Company" ) , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today ...
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
WARREN, N.J., Aug. 22, 2024 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc. ( NASDAQ: AQST ) ( "Aquestive" or the "Company" ) , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today ...
Aquestive Therapeutics ( AQST ) Reports Q2 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 72.73% and 59.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
